Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42，an FXR Agonist

SHANGHAI, Dec. 13, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announced today that it received Fast Track designation from the U.S. Food and Drug...

from PR Newswire: https://ift.tt/2JR6qCL